Zolgensma, the world's most expensive drug, brought in $186 million for Novartis in the fourth quarter, beating analysts expectations, STAT reported.
The one-time gene therapy treatment is priced at $2.1 million and is designed to treat spinal muscular atrophy in infants.
Novartis said about 200 patients have been treated with Zolgensma since it launched last June, according to STAT.
The drug is covered for 97 percent of patients with commercial plans; 50 percent of Medicaid patients are covered.
Read the full article here.